We planned to evaluate the effect of DC101 (anti-mouse VEGFR2 antibody) on AFP-positive Huh7 cell growth given that recent studies clearly showed the efficacy of ramucirumab, an anti-human VEGFR2 monoclonal antibody, for the treatment of AFP-positive advanced HCC in humans [8,9]. The gene discussed is AFP; the disease is hepatocellular carcinoma.